Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.45 |
| ▸ | ANPEP | P15144 | 6/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 4/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL30109857 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL8802761 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL3285972 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL9303138 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL2286761 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL9581376 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL9453845 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL7781917 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL10619258 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine SCHEMBL15111234 | 0.95 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643658-A1 | DIETARY PRODUCT FOR HYPOPROTEIC DIET | LABORATORIOS ERN S.A. (ES) | 2025-11-05 | — | — | EP | disclosed |
| CN-117603042-A | Preparation method and application of ketoleucine salt derivative | 河北天成药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-114246856-A | Composition containing amino acid derivative | 南京恒生制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-103922949-A | Calcium leucine chelate powder and processing method thereof | UNIV JILIN | 2014-07-16 | — | — | CN | disclosed |
| US-20100041622-A1 | Compositions containing aminoalkanes and aminoalkane derivatives | VIRUN, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010019255-A1 | COMPOSITIONS CONTAINING AMINOALKANES AND AMINOALKANE DERIVATIVES | VIRUN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041622-A1 | Compositions containing aminoalkanes and aminoalkane derivatives | TAAR5, PDE3A, PDE2A | SLC7A5 564/4885SLC1A3 177/4885SLC1A2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.